Solara Active Pharma Sciences Limited — Investor Meet, 11-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Solara Active Pharma Q2 FY26: Revenue INR 314 Cr (2% QoQ dip), EBITDA INR 35 Cr (11% margin, down 39%). A short-term Mangalore plant shutdown for upgrade impacted sales by INR 30-35 Cr. Post-upgrade, the facility successfully cleared a US FDA audit.

Management anticipates a stronger H2, reiterating FY26 outlook of 10% sales and 15-20% EBITDA growth. The focus is on sustainable, profitable growth, leveraging 75% regulated market sales and 70% capacity. Debt was reduced by INR 153 Cr in H1. Liquidity is expected to improve in two quarters. Management expresses confidence in strong underlying fundamentals.